Source comparison
CJC-1295 no DAC vs Hexarelin — Which Research Peptide?
A 2018 study published in Endocrinology found that GHRH analogs (like CJC-1295 no DAC) and ghrelin mimetics (like Hexarelin) produce fundamentally different growth hormone release patterns—GHRH analogs extend baseline GH secretion across multiple days, while g
This comparison does not assign a generated winner or score.
- A 2018 study published in Endocrinology found that GHRH analogs (like CJC-1295 no DAC) and ghrelin mimetics (like Hexarelin) produce fundamentally different growth hormone release patterns—GHRH analogs extend baseline GH secretion across multiple days, while ghrelin mimetics trigger acute pulsatile spikes within 30–60 minutes that resolve within 4–6 hours. The difference isn't just duration—it's mechanism. CJC-1295 no DAC amplifies the pituitary's natural GHRH response by protecting the peptide from degradation via dipeptidyl peptidase-IV (DPP-IV), while Hexarelin binds directly to ghrelin receptors (GHS-R1a) in both the pituitary and hypothalamus, bypassing the GHRH pathway entirely.
- Our team has worked with research-grade peptides across hundreds of institutional protocols. The gap between selecting CJC-1295 no DAC vs Hexarelin comes down to three variables most comparison charts never clarify: protocol timeline (acute vs chronic elevation), receptor target specificity (GHRH pathway vs ghrelin receptor), and downstream metabolic outcomes beyond GH itself.
- What's the practical difference between CJC-1295 no DAC vs Hexarelin for research applications?
- CJC-1295 no DAC (also called modified GRF 1-29) is a synthetic GHRH analog with a half-life of approximately 30 minutes that produces sustained GH elevation for 6–8 days per administration due to repeated endogenous pulsatile release. Hexarelin is a synthetic hexapeptide ghrelin mimetic with a half-life under 90 minutes that triggers a single acute GH pulse 30–60 minutes post-administration, resolving within 4–6 hours. Research labs conducting chronic elevation studies select CJC-1295; labs studying acute metabolic or cardiovascular response to GH spikes select Hexarelin.
- Direct answer: which peptide performs better in comparative research?
- This is where most overviews fail—they define each peptide but never establish the decision framework. The confusion stems from treating these as interchangeable GH secretagogues when they occupy entirely different mechanistic niches. CJC-1295 no DAC is not 'slow Hexarelin,' and Hexarelin is not 'acute CJC-1295.' One amplifies natural GHRH signalling; the other activates a parallel receptor pathway independent of GHRH entirely. This article covers the receptor-level mechanisms that differentiate them, the timeline and dosing patterns used in published research, and the protocol design criteria that determine which compound fits a given study objective.